Nuwellis Announces A Leading Northeastern U.S. Children's Hospital Has Initiated An Aquadex Ultrafiltration Program

Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardio-renal conditions, announced today that a leading Northeastern U.S. children's hospital has initiated an Aquadex Ultrafiltration Program. Pediatric nephrology and cardiology teams across the country continue to seek out the therapy for its minimal extracorporeal volume requirement and reliability in managing fluid-sensitive patients, driving steady growth in Nuwellis' expanding pediatric market.

Aquadex adoption continues to accelerate in high-acuity pediatric settings nationwide. Children's hospitals are integrating the therapy into care pathways for complex cardiac, cardio-renal, and critical care cases as teams look for controlled, predictable approaches to fluid management. This broader institutional uptake highlights both the clinical value physicians see in Aquadex and the strategic importance of the pediatric market within Nuwellis' long-term growth plan.